Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aurinia Pharmaceuticals ( (AUPH) ) has issued an announcement.
Aurinia Pharmaceuticals responded to a retracted LinkedIn post by an FDA official regarding voclosporin, affirming the positive benefit/risk profile of its product LUPKYNIS. The drug, approved by the FDA in January 2021 and for long-term use in April 2024, has shown sustained efficacy and safety in clinical studies, reinforcing Aurinia’s position in the autoimmune treatment market.
The most recent analyst rating on (AUPH) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
Aurinia Pharmaceuticals’ strong financial performance and positive earnings call are the most significant factors contributing to the stock’s score. The company’s revenue growth, improved profitability, and increased guidance are key strengths. However, the high valuation and overbought technical indicators present potential risks. The decrease in cash and investments due to share repurchases is a secondary concern.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia is a biopharmaceutical company focused on developing therapies for autoimmune diseases with high unmet medical needs. It introduced LUPKYNIS, the first FDA-approved oral therapy for adult patients with active lupus nephritis, and is developing aritinercept for potential autoimmune disease treatment.
Average Trading Volume: 2,075,227
Technical Sentiment Signal: Buy
Current Market Cap: $1.73B
See more data about AUPH stock on TipRanks’ Stock Analysis page.